Crohn Disease and Fracture Risk Assessment With FRAX

Abstract Background Studies are inconsistent whether people with Crohn disease (CD) have an increased fracture risk. This study showed that patients with Crohn’s disease (CD) had a higher ten year probability of fracture, assessed by the fracture assessment tool FRAX, and more fractures, but the proportion of CD patients with a fracture was not significantly higher than that of controls. Methods Forty-nine CD and 49 controls participated. All 98 completed a health questionnaire. A score with the fracture assessment tool FRAX > 15% was considered risk factor for fracture. Results Mean FRAX score for 49 CD was 10.1 ± 10.3% and for 49 controls 5.0 ± 3.9% (P = 0.002). The variables correlated with fracture were being female (P = 0.04) and having a fractured mother (P = 0.002). Conclusion The CD group had significantly higher FRAX scores and more fractures, but the proportion of CD subjects with a fracture was not significantly higher than that of controls.

Download Full-text

Is Inflammatory Bowel Disease a Risk Factor for Fracture? An Analysis Using the Fracture Risk Assessment Tool (FRAX): 2011 ACG Presidential Poster

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-01154 ◽

2011 ◽

Vol 106 ◽

pp. S431

Author(s):

Laura Targownik ◽

William Leslie ◽

Charles Bernstein ◽

Zoann Nugent

Keyword(s):

Risk Assessment ◽

Inflammatory Bowel Disease ◽

Risk Factor ◽

Fracture Risk ◽

Bowel Disease ◽

Assessment Tool ◽

Fracture Risk Assessment ◽

Risk Assessment Tool ◽

Fracture Risk Assessment Tool ◽

Inflammatory Bowel

Download Full-text

High Circulating Sphingosine 1-Phosphate is a Risk Factor for Osteoporotic Fracture Independent of Fracture Risk Assessment Tool

Calcified Tissue International ◽

10.1007/s00223-020-00731-1 ◽

2020 ◽

Vol 107 (4) ◽

pp. 362-370

Author(s):

Seung Hun Lee ◽

Jee Yang Lee ◽

Kyeong-Hye Lim ◽

Young-Sun Lee ◽

Seong-Hee Kim ◽

...

Keyword(s):

Risk Assessment ◽

Risk Factor ◽

Fracture Risk ◽

Osteoporotic Fracture ◽

Assessment Tool ◽

Fracture Risk Assessment ◽

Risk Assessment Tool ◽

Sphingosine 1 Phosphate ◽

Fracture Risk Assessment Tool

Download Full-text

Protocol for a multicentre, prospective cohort study of clinical, proteomic and genomic patterns associated with osteoporosis to develop a multidimensional fracture assessment tool: the PoCOsteo Study

BMJ Open ◽

10.1136/bmjopen-2019-035363 ◽

2020 ◽

Vol 10 (9) ◽

pp. e035363

Author(s):

Patricia Khashayar ◽

Hans Peter Dimai ◽

Nahid Moradi ◽

Noushin Fahimfar ◽

Safoora Gharibzadeh ◽

...

Keyword(s):

Risk Assessment ◽

Fracture Risk ◽

Prospective Cohort ◽

Assessment Tool ◽

Risk Model ◽

Ethics Committee ◽

Fracture Risk Assessment ◽

Assessment Model ◽

Fracture Assessment ◽

Medical University

IntroductionThe HORIZON 2020 project PoCOsteo aims (1) to develop a multidimensional fracture risk assessment tool which would take into account all factors known to be related to an individual’s fracture risk. The fracture risk model is intended to be developed in two different populations, namely a European and a Middle Eastern one; (2) to develop a medical device, which would measure and/or quantify proteomic as well as genomic factors as present in whole blood samples collected through finger prick; (3) to test the clinical applicability and the validity of prototypes of the to be developed point of care device at both clinical centres.Methods and analysisThis article presents the protocol of this prospective cohort that will be carried out independently at two different centres (Division of Endocrinology and Diabetology at the Medical University of Graz (MUG) as a clinic-based cohort, and Endocrinology and Metabolism Research Institute (EMRI) at the Tehran University of Medical Sciences (TUMS) as a population-based cohort). The final aim is to develop a fracture risk assessment model, which would include clinical risk factors, biochemical markers of bone turnover, as well as specific genomic factors. The derivation cohorts will consist of individuals aged 50 years and above. The period of observation for each patient will be 12 months; an extension phase, which would last for another 2 years, is also planned.Ethics and disseminationThese studies are conducted in accordance with the World Medical Association Declaration of Helsinki. The Iranian part was approved by the Research Ethics Committee of EMRI, TUMS. The Austrian part was approved by the Ethics Committee of the Medical University of Graz. Based on the gathered information, a multidimensional fracture assessment tool will be designed which will later be added to the PoCOsteo device.

Download Full-text